Squalene supplementation reduces cardiac injury biomarkers and blood pressure in ischemic heart disease: An open-label randomized controlled trial
Bioactive Molecules and Pharmaceuticals · 30.04.2026 · 3 (4) · 21-33
DOI: 10.31989/bmp.v3i4.1988 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Bioactive Molecules and Pharmaceuticals, online erschienen am 30.04.2026. Verfasst von Hossein Mirmiranpour und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background/Objectives: Ischemic heart disease (IHD) involves chronic inflammation and myocardial stress, reflected by an increase in cardiac injury markers including creatine kinase myocardial band (CK-MB), Troponin I, ischemia-modified albumin (IMA) and C-reactive protein (CRP). Squalene, a natural triterpene with antioxidant and anti-inflammatory properties, may offer cardio-protection.
Objectives
This study evaluated the effects of oral squalene (300, 600, or 900 mg/day) on systolic blood pressure (SBP), diastolic blood pressure (DBP), body mass index (BMI), and cardiac markers including CK-MB, CRP, IMA and Troponin I in stable IHD patients over 84 days.
Methods
180 participants were allocated to six groups (n=30 each): healthy controls, healthy + 600 mg/day squalene, untreated IHD controls, and IHD patients receiving 300, 600, or 900 mg/day squalene. Blood samples were collected on days 1, 14, 28, 56, and 84. Markers were measured by ELISA and immuno-turbidimetric methods. Data analyzed via repeated-measures ANOVA, one-way ANOVA with Tukey post-hoc, and t-tests (p
Zitieren
APA
Mirmiranpour, H., Baghdasaryan, I., & Martirosyan, D. (2026). Squalene supplementation reduces cardiac injury biomarkers and blood pressure in ischemic heart disease: An open-label randomized controlled trial. Bioactive Molecules and Pharmaceuticals, 3(4), 21-33. https://doi.org/10.31989/bmp.v3i4.1988
Vancouver
Mirmiranpour H, Baghdasaryan I, Martirosyan D. Squalene supplementation reduces cardiac injury biomarkers and blood pressure in ischemic heart disease: An open-label randomized controlled trial. Bioactive Molecules and Pharmaceuticals. 2026;3(4):21-33. doi:10.31989/bmp.v3i4.1988
BibTeX
@article{Mirmiranpour2026,
author = {Mirmiranpour, Hossein and Baghdasaryan, Isabella and Martirosyan, Danik},
title = {Squalene supplementation reduces cardiac injury biomarkers and blood pressure in ischemic heart disease: An open-label randomized controlled trial},
journal = {Bioactive Molecules and Pharmaceuticals},
year = {2026},
volume = {3},
number = {4},
pages = {21--33},
doi = {10.31989/bmp.v3i4.1988}
}
EUVIMED